Individual therapy

Treatment of essential or primary hypertension emphasizes not only the lowering of the elevated blood pressure, but also individualized therapy for each patient, providing each patient with minimized unnecessary side effects. The patient s cardiovascular morbidity and mortaUty should be decreased and end organ damage reversed or reduced (184,185). 

Licinio J, Wong ML (ed) (2002) Pharmacogenomics The search for individualized therapies. Wiley-VCH/John Wiley, Weinheim... 

To further improve sustained virologic response rates, different treatment approaches are currently under investigation. For example, individualized therapy durations on the basis of the HCV RNA concentration at baseline and early during therapy are the subject of clinical studies (Berg et al. 2006 Zeuzem et al. 2005a). In addition, triple therapy with other antiviral compounds, such as amantadine, has been evaluated in multiple studies, leading to contradictory results (Mangia et al. 2004). 

Pharmacogenomics The Search for Individualized Therapies. 11 Edited by J. Licinio and M.-L. Wong Copyright 2002 Wiley-VCH Verlag GmbH Co. KGaA ISBNs 3-527-30380-4 (Paper) 3-527-60075-2 (Electronic)... 

Pharmacogenomics The Search for Individualized Therapies. I 35 Edited by J. Licinio and M.-L. Wong ... 

Genomic pre-screening of patients for SNP mutations in drug metabolism will improve the utility of clinical trials by focusing attention on the response of specific subpopulations to drug treatment. The consequence of this approach is that it should be possible to industrialize the creation of individual therapies, although at a significant increase in cost. 

As in any field, extrapolation of in vitro data to the in vivo context warrants caution. Nevertheless, as revealed in this study, experimentally demonstrated down-regulation of ET-1 gene expression by HU corroborates the in vivo findings where ET-1 levels correlate with the clinical stage of SCA. Similarly, the balance between soluble and membrane-bound adhesive receptors of endothelial and other cells may dictate the triggering of acute clinical events. Individualized therapies for... 

The therapeutic objectives for hyperthyroidism are to normalize the production of thyroid hormone minimize symptoms and long-term consequences and provide individualized therapy based on the type and severity of disease, patient age and gender, existence of nonthyroidal conditions, and response to previous therapy. 

The average maintenance dose for most adults is about 125 mcg/day, but there is a wide range of replacement doses, necessitating individualized therapy and appropriate monitoring to determine an appropriate dose. 

---